Associated Papers
Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients-Case Series and Literature Review.
Popescu I et al.
Journal of Personalized Medicine, 2024
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
High Wnt2 Expression Confers Poor Prognosis in Colorectal Cancer, and Represents a Novel Therapeutic Target in BRAF-Mutated Colorectal Cancer.
Liu H et al.
Medicina (kaunas, Lithuania), 2023
Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples.
Gumà J et al.
Cancers, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition.
Jungwirth J et al.
Scientific Reports, 2022
Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
Tang M et al.
Journal of Inflammation Research, 2022
Spectrum of BRAF Aberrations and Its Potential Clinical Implications: Insights From Integrative Pan-Cancer Analysis.
Yi Q et al.
Frontiers in Bioengineering and Biotechnology, 2022
Genetic Profile of Adenomatoid Odontogenic Tumor and Ameloblastoma. A Systematic Review.
Marín C et al.
Frontiers in Oral Health, 2021
Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, 2019
Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile.
Richetta AG et al.
Oncotarget, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA.
Wu T et al.
Nucleic Acids Research, 2018
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A et al.
Acta Neuropathologica Communications, 2016
Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran.
Koochak A et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2015
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A et al.
Bmc Cancer, 2015
Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
Mohamed Suhaimi NA et al.
Molecular Oncology, 2015
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
Imamura Y et al.
Molecular Cancer, 2014
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Kalikaki A et al.
Plos One, 2014
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM et al.
Clinical Colorectal Cancer, 2013
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A et al.
Critical Reviews in Oncology/hematology, 2013
A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer.
Galbiati S et al.
Plos One, 2013
High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT et al.
Archives of Pathology & Laboratory Medicine, 2012
Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.
Sylvester BE et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Differential high-resolution melting analysis for the detection of K-ras codons 12 and 13 mutations in pancreatic cancer.
Zhang C et al.
Pancreas, 2011
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.
van Eijk R et al.
Plos One, 2011
SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.
Fariña Sarasqueta A et al.
The Journal of Molecular Diagnostics : Jmd, 2011
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue.
Tol J et al.
Journal of Cellular and Molecular Medicine, 2010
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants.
Hocker T et al.
Human Mutation, 2007
KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.
Karim B et al.
Cancer Biomarkers : Section a of Disease Markers, 0
A Cross-Sectional Study for Evaluation of KRAS and BRAF Mutations by Reverse Dot Blot, PCR-RFLP, and Allele-Specific PCR Methods Among Patients with Colorectal Cancer.
Sheikhsofla F et al.
Avicenna Journal of Medical Biotechnology, 0